BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
BriaCell Therapeutics Corp. recently announced today it has added Mayo Clinic, Jacksonville, FL, as a clinical site in the Phase 1/2 study of BriaCell’s lead candidate, Bria-IMT, with Incyte’s PD-1 inhibitor, retifanlimab, in advanced breast cancer.
“We are thrilled to be working with the clinical experts at Mayo Clinic and other top cancer centers across the United States. We believe that with our immunotherapy’s novel mechanism of action, continuous innovations and improvements, and a Fast Track path to approval, we have great potential to improve patients’ lives,” said Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. For more information, visit https://briacell.com/.
Total Page Views: 962
